No clinical efficacy or safety issues raised and no additional clinical studies required by FDA to support approval Company plans to engage with FDA toward expeditious resolution of outstanding items NEW YORK, May 2, 2022 /PRNewswire/ –…Original Article
Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine
